Advanced Filters
noise

Lung Disease Clinical Trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 3,040 clinical trials
S Scott Miller

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

18 years of age All Phase 1
J Justyna Bartoszko, MD MSc FRCPC

Delayed Cold-Stored Platelets -PLTS-1

PLTS-1 is a multicentre, randomized, controlled, pilot trial, using a conventional, parallel group, two-armed design at 2 cardiac surgery centres in Canada. The study is designed to assess the feasibility of a future, definitive RCT to determine the non-inferiority of cold-stored platelets compared to conventional platelets with respect to hemostatic …

18 years of age All Phase 2
I Inna Markovna Chen, MD

Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)

Pancreatic and biliary tract cancer are ones of the leading causes of cancer-related deaths. During the course of illness, these patients often experience marked physical suffering, psychological distress and frequent unplanned resource-demanding hospitalized care. Patients with pancreatic and lung cancer have highest rates of unplanned hospitalizations. Investigator initiated prospective "Study …

18 years of age All Phase N/A
M Megan Barrett

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors.

18 years of age All Phase 1
Y Yang Liu, M.D.

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research. The clinical recommend dose of this product is 50mg/day, and the dose used in this study is 100mg/day, which is larger than the …

18 - 65 years of age All Phase 2
G Gabriel Tinoco, MD

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

18 years of age All Phase 1
N Noortje van Dijk, Msc

PET-imaging of Two Vartumabs in Patients With Solid Tumors

VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS). Oncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal …

18 years of age All Phase N/A
M Ming Ye, Master

Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors

Stereotactic Body Radiation Therapy(SBRT) for spinal metastases has been proved a good results in pain relieve and local control, However,the longterm of efficacy and safety of this regimen is unclear.The purpose of the study is to evaluate the longterm outcome of this therapeutic regimen in selective patients who will be …

18 - 85 years of age All Phase 2
Q Qiu Li, PhD

Personalized DC Vaccine for Postoperative Cancer

The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

18 - 100 years of age All Phase 1
B Barbara Pistilli, Dr

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

Alterations in the HER2 gene are involved in the development of cancer. These abnormalities are found at highly variable rates (from approximately 2% to 60%) in cancers of the lung, breast, stomach, bile ducts, salivary glands, colon, endometrium, uterus, bladder, bones, blood, etc. Zanidatamab is an anti-cancer drug that acts …

18 years of age All Phase 2

Simplify language using AI